Reata Pharma (RETA) Prices 5.5M Class A Common Stock IPO at $11/Share

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced the pricing of its initial public offering of 5,500,000 shares of its Class A common stock at $11.00 per share, before underwriting discounts and commissions. Reata has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of its Class A common stock at the initial public offering price. The shares of Class A common stock are expected to begin trading on The NASDAQ Global Market on May 26, 2016, under the ticker symbol “RETA.”

*** NOTE: The company was recently looking to offer 4 million shares and expected a pricing range of $14 - $16 per share.

Reata anticipates the proceeds from the offering (after deducting underwriting discounts and commissions and estimated offering expenses) will be approximately $52.5 million, excluding any exercise of the underwriters' option to purchase additional shares. Reata intends to use the net proceeds from the offering to advance the development of its lead product candidate, bardoxolone methyl, through a Phase 3 trial and additional Phase 2 programs, to advance the development of its product candidate omaveloxolone through Phase 2 clinical trials, and to provide funds for working capital and other general purposes, including preclinical studies and clinical trials.

Citigroup, Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on May 25, 2016. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering is being made only by means of a written prospectus. A copy of the final prospectus relating to these securities may be obtained for free from:

Citigroup Global Markets Inc.,c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, telephone: 1-800-831-9146;

Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, telephone: 1-631-274-2806, or fax 1-631-254-7140; or

Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Email: [email protected], or telephone at (800) 747-3924

You May Also Be Interested In

• Charter Communications closes $4.75 billion senior secured notes offering
• Privia Health names Opella Ernest to its board of directors
• Enovix names interim CEO after Raj Talluri resignation